	US 12,221,480 B2
	Methods for selective expansion of delta-3 gamma delta T-cell populations and compositions thereof
Aya Jakobovits, Beverly Hills, CA (US); Daulet Kadyl Satpayev, Redwood City, CA (US); Orit Foord, Foster City, CA (US); Yifeng Frank Jing, Hayward, CA (US); Hui Shao, Foster City, CA (US); Jason Michael Romero, East Palo Alto, CA (US); Mary Michael Brody, Menlo Park, CA (US); and Matthew Ian Hoopes, Menlo Park, CA (US)
Assigned to ADICET THERAPEUTICS, INC.
Appl. No. 16/764,796
Filed by ADICET THERAPEUTICS, INC., Redwood City, CA (US)
PCT Filed Nov. 15, 2018, PCT No. PCT/US2018/061384 § 371(c)(1), (2) Date May 15, 2020, PCT Pub. No. WO2019/099744, PCT Pub. Date May 23, 2019.
Claims priority of provisional application 62/586,782, filed on Nov. 15, 2017.
Prior Publication US 2023/0257462 A1, Aug. 17, 2023
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); C12N 5/0783 (2010.01)

CPC C07K 16/2809 (2013.01) [A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464424 (2023.05); C12N 5/0636 (2013.01); C07K 2317/92 (2013.01); C12N 2510/00 (2013.01)]

28 Claims

1. An antibody or fragment thereof that binds an epitope specific to a δ3 γδ TCR, wherein the antibody or fragment thereof comprises:

(i) a heavy chain variable region/light chain variable region (HCVR/LCVR) sequence pair selected from the group consisting of SEQ ID NOs: 1/8, 2/9, 3/10, 4/11, 5/12, 6/13, and 7/14; or a HCVR/LCVR pair comprising

(ii) the six complementarity determining regions (CDRs) of a HCVR/LCVR sequence pair selected from the group consisting of SEQ ID NOs: 1/8, 2/9, 3/10, 4/11, 5/12, 6/13, and 7/14.